Guggenheim lowers ArriVent BioPharma stock price target to $28
Guggenheim cut its price target on ArriVent BioPharma (AVBP) to $28 from $30, keeping a Buy rating. The stock is down 53% in six months, trading at $13.01. The firm adjusted estimates after Q3 2026 results, including a Phase 3 miss for FURVENT. ArriVent has $393.2M in cash, expected to last until mid-2028. Analysts have mixed views on its prospects.
How this was made
The 30-second read
Why it matters
Analyst target revisions reflect immediate market sentiment but do not change the underlying cash position or pipeline timeline.
Market read
The price‑target cuts may trigger short‑term volatility in AVBP, while the broader biotech sector remains sensitive to trial outcomes.
What to watch
Upcoming data from the firm’s firmonertinib trial in 2027 could offset short‑term pressure.
Background
ArriVent BioPharma reported Q3 2026 results, including a Phase 3 trial miss and early data from other candidates.
Ticker impact
Guggenheim lowered its price target on ArriVent BioPharma (AVBP) to $28 from $30 after the company's Q3 2026 results and a Phase 3 miss.
downward pressure as investors price in the lower target
Analyst target reductions typically lead to short-term price declines, especially after a miss in a pivotal trial.
Market effects
Biotech sector may see broader caution on trial‑risk stocks.
US biotech investors may adjust exposure to early‑stage oncology assets.
Limited to investors tracking US‑listed biotech companies.
Counterpoint
Some investors may view the target cut as an overreaction given long‑term pipeline potential.
Key entities
- AnalystGuggenheim
Lowered price target to $28.
- CompanyArriVent BioPharma
Biotech firm with multiple trial updates.

